Restore Facial Volume with Lipoderma
If you’ve been researching ways to restore lost facial volume or correct contour irregularities without surgery or traditional fillers, you may have come across Lipoderma by BrightCyte – a new option in regenerative aesthetics that’s gaining attention among plastic surgeons and patients alike.
Lipoderma belongs to a growing class of adipose (fat)-derived allografts such as alloClae and Renuva/Leneva. Lipoderma delivers real adipose tissue components that help your body rebuild healthy, natural-looking fat where it’s been lost over time.
Below, we’ll explain what Lipoderma is, how it works, and what makes it unique and how it differentiates from alloClae and Renuva/Leneva.
What Is Lipoderma?
Lipoderma is an adipose tissue allograft – meaning it’s made from carefully processed donor fat.
Unlike many fillers that are made of hyaluronic acid or synthetic materials, Lipoderma contains real fat cells (adipocytes) and extracellular matrix (ECM) in a ratio the company reports to be biologically active – about 90% adipocytes and 10% ECM. The product is devitalized, meaning the fat cells are no longer living, but they retain all the natural signaling molecules that help your body remodel and integrate the graft into your own tissue.
How is Lipoderma Sold and How Big are the Vials?
Lipoderma comes frozen and is defrosted before use. Once defrosted, it must be used within 4 hours. This is different than alloClae and Leneva, which are both stored at room temperature.
As of Fall 2025, Lipoderma comes in 1.5cc vials. Each vial contains 1.5cc of flowable fat tissue, which can be precisely injected into areas of volume loss such as the face or other contour depressions. In comparison, alloClae comes in 12.5, 25, 50, and 100 cc vials while Renuva/Leneva comes in 1.5 and 3 cc vials.
Where Can Lipoderma Be Injected?
Like Leneva/Renuva, Lipoderma can be injected into the soft tissues of the body and face to restore natural volume and improve contour.
Currently, alloClae is approved for use in the body only . This is because the formulation includes a small amount of oil that helps the product flow more easily, and that ingredient isn’t yet optimized for the delicate tissues of the face. The manufacturer may in the future produce a face-specific version.
How Does Lipoderma Work?
Once injected, Lipoderma must come into contact with healthy surrounding fat. This allows the tissue to act as a scaffold for your body to remodel and replace it with your own new fat cells over time.
What’s in Lipoderma?
Lipoderma is composed of:
- Adipocytes (fat cells) – about 90% of the product
- Extracellular matrix (ECM) – about 10%, providing structure and signaling support
- Preservatives – Trehalose and human serum albumin (HSA), used as cryoprotectants
- Particle size – approximately 0.7 mm, allowing smooth injection and integration
Lipoderma vs. Renuva / Leneva vs. AlloClae: What’s the Difference?
While Lipoderma, Renuva, and AlloClae all fall under the umbrella of fat-derived regenerative injectables, they differ in important ways:
Feature
Lipoderma
Renuva / Leneva
alloClae
Composition
90% adipocytes + 10% ECM
100% ECM (no fat cells)
ECM with added adipose components and lubricating biocompatible oil
Processing
Cryopreserved with Trehalose & HSA
Decellularized adipose matrix
Proprietary preservation
Injectable Form
Flowable fat tissue
Powder reconstituted with saline
Flowable tissue
Immediate Volume
Yes
Minimal (gradual tissue regeneration)
Yes
Integration
Remodels into patient’s own fat
Stimulates patient’s fat to regrow
Remodels into patient’s own fat
Price
+++
++++
++
Volume Options
Currently 1.5cc; larger sizes anticipated mid-2026
1.5 & 3 cc
12.5, 25, 50, and 100 cc
In short:
- Lipoderma provides immediate volume with real adipose tissue, not just a matrix scaffold.
- Renuva / Leneva relies solely on your body’s response to an ECM-only product.2
- alloClae offers larger-volume formulations but at higher cost, with slightly different tissue characteristics. alloClae cannot be injected into the face.
Lipoderma aims to combine the biologic integration of Renuva / Leneva with the instant results and feel of fat transfer – without the need for liposuction or surgical fat harvest.
Who May be a Good Candidate for Lipoderma?
Lipoderma is best suited for patients who:
- Have mild to moderate fat loss or contour irregularities in the face, back of the hands, or body (hip dips or breast)
- Want natural, lasting volume without surgery
- Have healthy surrounding fat for tissue integration
- Are not actively taking GLP-1 medications (like semaglutide or tirzepatide), since these drugs can alter fat metabolism and affect outcomes
Because the data on metabolic impacts are still early, most experts recommend avoiding GLP-1 use around the time of treatment until more research becomes available.
How Long Does Lipoderma Last?
Initial studies and clinical experience suggest long-term durability. In the patients with the longest follow-up (presently, two years), roughly 75% of the injected fat volume remains. Over time, this remodeled tissue behaves like your own fat – soft, pliable, and responsive to weight changes.
The Bottom Line
Lipoderma represents an exciting advance in fat restoration technology, combining the biological benefits of living fat tissue with the safety, sterility, and convenience of an off-the-shelf injectable product.
With its flowable consistency, preserved signaling molecules, and long shelf life, Lipoderma gives surgeons a versatile new tool – and patients a way to restore natural volume without the downtime of fat transfer surgery.
Interested in Lipoderma treatments?
Our office offers consultations to help you determine whether Lipoderma or another regenerative filler is right for your goals. Schedule your appointment today to learn more.
[1] Kokai LE, Sivak WN, Schilling BK, Karunamurthy A, Egro FM, Schusterman MA, Minteer DM, Simon P, D’Amico RA, Rubin JP. Clinical Evaluation of an Off-the-Shelf Allogeneic Adipose Matrix for Soft Tissue Reconstruction. Plast Reconstr Surg Glob Open. 2020 Jan 27;8(1):e2574. doi: 10.1097/GOX.0000000000002574. PMID: 32095393; PMCID: PMC7015604. https://pmc.ncbi.nlm.nih.gov/articles/PMC6358185/
[2] Kokai L.E., Schilling B.K., Chnari E., Huang Y.C., Imming E.A., Karunamurthy A., Khouri R.K., D’Amico R.A., Coleman S.R., Marra K.G., Rubin J.P. Injectable Allograft Adipose Matrix Supports Adipogenic Tissue Remodeling in the Nude Mouse and Human. Plast Reconstr Surg. 2019;143:299e. https://pubmed.ncbi.nlm.nih.gov/30688888/
Contact Us To Schedule Your Consultation
Our Latest Posts